FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2131756075> ?p ?o ?g. }

• W2131756075 endingPage "745" @default.
• W2131756075 startingPage "735" @default.
• W2131756075 abstract "This multicenter, 6-week, double-blind, placebo-controlled, parallel-group study compared the efficacy and safety of oxaprozin 1200 mg once daily with that of nabumetone 1000 mg once daily in patients with moderate-to-severe osteoarthritis (OA) of the knee. To be eligible, patients had to experience a flare of OA within 2 weeks of discontinuing their usual OA medication (nonsteroidal anti-inflammatory drug or analgesic). Eligible patients were assessed at baseline and then randomized to receive oxaprozin (n = 109), nabumetone (n = 110), or placebo (n = 109). Efficacy assessments were performed at weeks 1, 2, 4, and 6. Primary efficacy variables included knee pain on weight bearing, knee pain on motion, and patient's and physician's global assessments of OA. Secondary efficacy variables included pain intensity, time to walk 50 feet, and duration of morning stiffness. Safety was evaluated by use of routine laboratory analyses; physical examination at screening, baseline, and week 6 (or study termination); assessment of symptoms at baseline and at each visit; and testing stools for occult blood at screening and between week 4 and the final visit. Adverse events were monitored throughout the study. Between-group differences in efficacy variables were evident by week 1. The mean change in improvement from baseline with oxaprozin compared with placebo was statistically significant in favor of oxaprozin at weeks 1, 2, 4, and 6 for all primary efficacy variables. The mean change in improvement from baseline with nabumetone compared with placebo, however, was statistically significant only at week 1 for knee pain on motion, patient's global assessment, and physician's global assessment. The mean change in improvement from baseline was statistically significant (P < or = 0.035) in favor of oxaprozin versus nabumetone at weeks 2 and 6 for all four primary efficacy variables and also at week 4 for knee pain on motion. The incidence of adverse clinical events between treatment groups was not statistically significant. However, nine oxaprozin-treated patients had asymptomatic liver enzyme elevations reported as adverse events. Four of these patients had reversible elevations of aspartate aminotransferase and alanine aminotransferase greater than three times the upper limit of normal range (P < 0.05); two of these patients were taking other medications known to induce liver enzyme abnormalities. The study showed that oxaprozin 1200 mg once daily was statistically significantly more efficacious than nabumetone 1000 mg once daily for the treatment of patients with moderate-to-severe OA of the knee. Both drugs were clinically well tolerated." @default.
• W2131756075 created "2016-06-24" @default.
• W2131756075 creator A5007653088 @default.
• W2131756075 creator A5014820143 @default.
• W2131756075 creator A5021514928 @default.
• W2131756075 creator A5034922033 @default.
• W2131756075 creator A5036959838 @default.
• W2131756075 creator A5045035998 @default.
• W2131756075 creator A5045839155 @default.
• W2131756075 creator A5052221041 @default.
• W2131756075 creator A5052315484 @default.
• W2131756075 creator A5061783470 @default.
• W2131756075 creator A5065845915 @default.
• W2131756075 creator A5070979458 @default.
• W2131756075 creator A5081936185 @default.
• W2131756075 creator A5085202627 @default.
• W2131756075 date "1995-07-01" @default.
• W2131756075 modified "2023-10-16" @default.
• W2131756075 title "Comparison of the efficacy and safety of oxaprozin and nabumetone in the treatment of patients with osteoarthritis of the knee" @default.
• W2131756075 cites W144247879 @default.
• W2131756075 cites W1972309781 @default.
• W2131756075 cites W2032078587 @default.
• W2131756075 cites W2058147305 @default.
• W2131756075 cites W2065466345 @default.
• W2131756075 cites W2116003402 @default.
• W2131756075 cites W2131969324 @default.
• W2131756075 doi "https://doi.org/10.1016/0149-2918(95)80050-6" @default.
• W2131756075 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8565037" @default.
• W2131756075 hasPublicationYear "1995" @default.
• W2131756075 type Work @default.
• W2131756075 sameAs 2131756075 @default.
• W2131756075 citedByCount "25" @default.
• W2131756075 countsByYear W21317560752012 @default.
• W2131756075 countsByYear W21317560752017 @default.
• W2131756075 countsByYear W21317560752018 @default.
• W2131756075 countsByYear W21317560752020 @default.
• W2131756075 countsByYear W21317560752022 @default.
• W2131756075 crossrefType "journal-article" @default.
• W2131756075 hasAuthorship W2131756075A5007653088 @default.
• W2131756075 hasAuthorship W2131756075A5014820143 @default.
• W2131756075 hasAuthorship W2131756075A5021514928 @default.
• W2131756075 hasAuthorship W2131756075A5034922033 @default.
• W2131756075 hasAuthorship W2131756075A5036959838 @default.
• W2131756075 hasAuthorship W2131756075A5045035998 @default.
• W2131756075 hasAuthorship W2131756075A5045839155 @default.
• W2131756075 hasAuthorship W2131756075A5052221041 @default.
• W2131756075 hasAuthorship W2131756075A5052315484 @default.
• W2131756075 hasAuthorship W2131756075A5061783470 @default.
• W2131756075 hasAuthorship W2131756075A5065845915 @default.
• W2131756075 hasAuthorship W2131756075A5070979458 @default.
• W2131756075 hasAuthorship W2131756075A5081936185 @default.
• W2131756075 hasAuthorship W2131756075A5085202627 @default.
• W2131756075 hasConcept C126322002 @default.
• W2131756075 hasConcept C142724271 @default.
• W2131756075 hasConcept C168563851 @default.
• W2131756075 hasConcept C1862650 @default.
• W2131756075 hasConcept C197934379 @default.
• W2131756075 hasConcept C204787440 @default.
• W2131756075 hasConcept C27081682 @default.
• W2131756075 hasConcept C2776164576 @default.
• W2131756075 hasConcept C2777456732 @default.
• W2131756075 hasConcept C2778484676 @default.
• W2131756075 hasConcept C2779279471 @default.
• W2131756075 hasConcept C2779944601 @default.
• W2131756075 hasConcept C2780820201 @default.
• W2131756075 hasConcept C42219234 @default.
• W2131756075 hasConcept C71924100 @default.
• W2131756075 hasConcept C98274493 @default.
• W2131756075 hasConceptScore W2131756075C126322002 @default.
• W2131756075 hasConceptScore W2131756075C142724271 @default.
• W2131756075 hasConceptScore W2131756075C168563851 @default.
• W2131756075 hasConceptScore W2131756075C1862650 @default.
• W2131756075 hasConceptScore W2131756075C197934379 @default.
• W2131756075 hasConceptScore W2131756075C204787440 @default.
• W2131756075 hasConceptScore W2131756075C27081682 @default.
• W2131756075 hasConceptScore W2131756075C2776164576 @default.
• W2131756075 hasConceptScore W2131756075C2777456732 @default.
• W2131756075 hasConceptScore W2131756075C2778484676 @default.
• W2131756075 hasConceptScore W2131756075C2779279471 @default.
• W2131756075 hasConceptScore W2131756075C2779944601 @default.
• W2131756075 hasConceptScore W2131756075C2780820201 @default.
• W2131756075 hasConceptScore W2131756075C42219234 @default.
• W2131756075 hasConceptScore W2131756075C71924100 @default.
• W2131756075 hasConceptScore W2131756075C98274493 @default.
• W2131756075 hasIssue "4" @default.
• W2131756075 hasLocation W21317560751 @default.
• W2131756075 hasLocation W21317560752 @default.
• W2131756075 hasOpenAccess W2131756075 @default.
• W2131756075 hasPrimaryLocation W21317560751 @default.
• W2131756075 hasRelatedWork W1983113875 @default.
• W2131756075 hasRelatedWork W2000361523 @default.
• W2131756075 hasRelatedWork W202007074 @default.
• W2131756075 hasRelatedWork W2092980618 @default.
• W2131756075 hasRelatedWork W2253217589 @default.
• W2131756075 hasRelatedWork W2313237820 @default.
• W2131756075 hasRelatedWork W2562722334 @default.
• W2131756075 hasRelatedWork W2936315636 @default.
• W2131756075 hasRelatedWork W3009095920 @default.

• next